News Channels

05 Jan 2023 IntoCell Enters into Development and License Option Agreement with ADC Therapeutics
05 Jan 2023 Duality Biologics Announces License Agreement of its Next-generation ADC platform with Adcendo
05 Jan 2023 Nirsevimab US regulatory submission accepted for the prevention of RSV lower respiratory tract disease in infants and children up to age 24 months
04 Jan 2023 Roivant Announces Statistically Significant and Clinically Meaningful Results from the Induction Period of TUSCANY-2, a Large Global Phase 2b Study of Subcutaneous RVT-3101 for the Treatment of Ulcerative Colitis in Both the Overall and the Biomarker Posi
04 Jan 2023 Immunitas Therapeutics Announces First Patient Dosed in Phase 1/2a Study of IMT-009
04 Jan 2023 NorthStar Medical Radioisotopes and Inhibrx Enter into Collaboration Agreement for the Development and Production of Radiopharmaceutical Candidates
04 Jan 2023 Arugula Sciences Announces Company Launch with FDA Phase 1 Approval for Osteoarthritis Therapy
04 Jan 2023 Ventus Therapeutics Nominates Potential First-in-Class cGAS Inhibitor VENT-03 as Inaugural Development Candidate in cGAS Franchise
04 Jan 2023 Horizon Therapeutics plc Announces First Patient Enrolled in Phase 2 Trial Evaluating Daxdilimab for the Treatment of Discoid Lupus Erythematosus
04 Jan 2023 Belharra Therapeutics Announces Broad Collaboration with Genentech to Discover and Develop Novel Medicines Across Multiple Therapeutic Areas
04 Jan 2023 Biogen and Alcyone Therapeutics Announce License and Collaboration Agreement to Evaluate a Novel Device to Improve Patient Experience and Access to Neurological ASO Therapies
04 Jan 2023 Evaxion receives approval from FDA to proceed with the clinical Phase 2b study for EVX-01
04 Jan 2023 Jasper Therapeutics Announces Positive Clinical Data from a Phase I/II Trial of Briquilimab as a Conditioning Treatment in Sickle Cell Disease and Beta Thalassemia
04 Jan 2023 First Patient Enrolled in Phase 3 Trial Evaluating Abelacimab in High-Risk Patients with Atrial Fibrillation Deemed Unsuitable for Current Anticoagulants
04 Jan 2023 Orano Med Starts Phase I Trial With Alpha Radioligand Therapy 212Pb-GRPR in Patients With Solid Tumors
04 Jan 2023 ENHERTU® Type II Variation Application Validated by EMA for the Treatment of HER2 Mutant Metastatic Non-Small Cell Lung Ca
03 Jan 2023 OncoC4 Announces First Patient Dosed in PRESERVE-004, a Phase 2 Clinical Trial of ONC-392 in Combination with KEYTRUDA® (Pembrolizumab) in Patients with Platinum-Resistant Ovarian Cancer
03 Jan 2023 Janssen Submits Marketing Authorisation Application to the European Medicines Agency Seeking Approval of Talquetamab for the Treatment of Patients with Relapsed or Refractory Multiple Myeloma
03 Jan 2023 PDS Biotech Announces Exclusive Global License Agreement for Investigational IL-12 Tumor-Targeted Cytokine from Merck KGaA, Darmstadt, Germany
03 Jan 2023 HotSpot Therapeutics Announces FDA Clearance of IND Application for HST-1011, An Investigational Small Molecule Allosteric Inhibitor of CBL-B

La Merie Biologics

FREE Weekly News Bulletin

Sign Up

2021 Sales ofAntibodies & Proteins

New Product Alert

For La Merie Publishing

Sign Up